Skip to main content
ADBIOTECH Co.,Ltd. logo

ADBIOTECH Co.,Ltd. — Investor Relations & Filings

Ticker · 179530 ISIN · KR7179530001 KO Manufacturing
Open in API
Filings indexed 415 across all filing types
Latest filing 2025-06-09 Capital/Financing Update
Country KR South Korea
Listing KO 179530

About ADBIOTECH Co.,Ltd.

http://www.adbiotech.com

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the development and commercialization of immune antibodies. The company's core competency is IgY (Immunoglobulin in Yolk) technology, which utilizes antibodies derived from eggs to create alternatives to conventional vaccines and antibiotics. Its product portfolio targets the livestock, aquaculture, and human health sectors, with applications for disease prevention and treatment in animals like salmon and shrimp, as well as human-focused developments for conditions related to Helicobacter pylori and cholesterol. The company manages the entire value chain from research and development to production and sales. ADBIOTECH is also expanding its technological capabilities into VHH (nanobody) technology, with a strategic focus on the global companion animal market.

Recent filings

Filing Released Lang Actions
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding the issuance of convertible bonds (전환사채권 발행결정). This type of filing is a regulatory disclosure concerning capital structure changes and financing activities. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate category for announcements regarding new share issues, stock splits, or other capital changes, including convertible bond issuances that impact share capital.
2025-06-09 Korean
주요사항보고서(자기전환사채매도결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding the decision to sell previously acquired convertible bonds (자기전환사채매도결정). This type of regulatory filing concerns the company's capital structure and financing activities. Since it specifically details the sale of financial instruments (convertible bonds) to raise capital, it falls under the 'Capital/Financing Update' category.
2025-06-09 Korean
[기재정정]주주총회소집결의 (임시주주총회)
AGM Information Classification · 98% confidence The document is a formal notice regarding the convocation of an Extraordinary General Meeting (EGM) and a subsequent correction notice regarding the meeting date. In the context of corporate filings, documents related to the convocation of shareholder meetings, including agenda items and meeting logistics, fall under Proxy Solicitation & Information Statement (PSI) as they provide shareholders with the necessary information to participate and vote in the meeting.
2025-06-09 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Supervisory Service (FSS) and the Korea Exchange (KRX) regarding a decision to issue new shares through a third-party allocation (유상증자결정). This type of filing is a mandatory regulatory disclosure in South Korea for significant corporate events, specifically capital changes. Since it details the issuance of new shares and capital structure changes, it falls under the 'Share Issue/Capital Change' category.
2025-06-09 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from AdBiotech, specifically detailing a 'Decision on Paid-in Capital Increase' (유상증자결정). This is a formal regulatory filing required by the Korea Exchange (KRX) to announce capital structure changes, specifically a third-party allocation of new shares. It contains detailed financial data regarding the issuance, purpose of funds, and the identity of the third-party investor. This falls under the category of share issuance and capital changes.
2025-06-09 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange) regarding a 'Decision on Paid-in Capital Increase' (유상증자 결정). It details the issuance of new shares, the purpose of the capital raise (operating funds), the third-party allocation method, and specific financial data regarding the issuer and the investor. This falls under the category of share issuance and capital changes.
2025-06-09 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.